Rafael Holdings (RFL) has shared an update.
Mark McCamish stepped down as director of Rafael Holdings, Inc. on August 5, 2024, and was promptly replaced by Mark N. Stein, MD, who brings a wealth of medical expertise to the board. As an experienced medical oncologist and seasoned clinical trial leader, Dr. Stein’s knowledge from his tenure at Columbia University and Rutgers University will provide valuable insights, particularly in the realm of immunotherapy for prostate and kidney cancer, to the company’s governance and strategic direction.
See more insights into RFL stock on TipRanks’ Stock Analysis page.